The recently reported happenings in the bio-tech market, with emphasis on
Teleflex Incorporated (TFX), are far-reaching. TFX is receiving considerable attention, including Westwood Holdings Group Inc. boosting its stake in the company. Some question if TFX is a smart addition to portfolios, while others consider it a top growth stock for the long-term. Notably,
Teleflex's Q2 earnings surpassed estimates, which led to increased profit forecast following a share buyback announcement. The company has also announced the Teleflex Center for Antimicrobial Protection, and the limited market release of the Wattson™ Temporary Pacing Guidewire. These launches, combined with its acquisition of Palette Life Sciences, signal a strategic stance for expansion in its sector. Despite some market uncertainties, many analysts remain bullish on TFX's future, some have their
target price set at $265.57, while some speculate the fair value at $370. However, there are concerns as returns on capital at Teleflex paint a worrying picture. Furthermore, there are indications of shrinking earnings driving a three-year loss for shareholders.
Teleflex Incorporated TFX News Analytics from Fri, 02 Dec 2016 08:00:00 GMT to Sun, 22 Sep 2024 15:20:12 GMT -
Rating 2
- Innovation 4
- Information 5
- Rumor -1
